{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:59:19Z","timestamp":1787068759808,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>\n                    Children with neuroblastoma (NB) and opsoclonus-myoclonus-ataxia syndrome (OMAS) have a favorable oncologic outcome and overall survival. In contrast, despite intensive multidrug immunomodulation, the neurologic outcome is complicated by the relapsing nature of the neurologic symptoms and long-term neurobehavioral sequelae. Being associated with low-risk NB, there exists an ambiguity in the current literature regarding the administration of chemotherapy in these children. We reviewed our archives for children with NB-OMAS over a 22-year (January 1996 to January 2018) period. Eighteen children (10 female) with a median age at diagnosis of 23 months had NB-OMAS and were included. They had stage 1 (9\/18; 50%), 2 (1\/18; 5.5%), 3 (7\/18; 39%), and 4 (1\/18; 5.5%) disease according to the International Neuroblastoma Staging System. Multimodality therapy included surgery (16\/18; 89%), chemotherapy (11\/18; 61%), and immunomodulatory therapy (10\/18; 55%). Complete oncologic remission was achieved in all children. Relapse of OMAS and presence of neurologic sequelae were observed in 1 (5.5%) and 5 (28%) cases, respectively. Presence of neurologic sequelae was significantly associated with low-tumor stage (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.036) and treatment without chemotherapy (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.003). Chemotherapy administration was the only variable significantly predicting a favorable neurologic outcome (95% confidence interval: 0.26-1.40,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.01). To conclude, our study including a limited cohort of patients highlights a favorable neurologic outcome associated with chemotherapy administration in children with NB-OMAS. However, further studies with larger sample size need to be conducted before drawing any definite conclusions.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000002131","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T10:12:14Z","timestamp":1616753534000},"page":"e924-e929","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Neuroblastoma With Opsoclonus-Myoclonus-Ataxia Syndrome: Role of Chemotherapy in the Management: Experience From a Tertiary Care Center in a Resource-limited Setting"],"prefix":"10.1097","volume":"43","author":[{"given":"Sachit","family":"Anand","sequence":"first","affiliation":[{"name":"Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Agarwala","sequence":"additional","affiliation":[{"name":"Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishesh","family":"Jain","sequence":"additional","affiliation":[{"name":"Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, BRAIRCH, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Dhua","sequence":"additional","affiliation":[{"name":"Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheffali","family":"Gulati","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Seth","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddur","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Jana","sequence":"additional","affiliation":[{"name":"Radiodiagnosis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devasenathipathy","family":"Kandasamy","sequence":"additional","affiliation":[{"name":"Radiodiagnosis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veereshwar","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fneur.2017.00468","article-title":"Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study","volume":"8","author":"Pranzatelli","year":"2017","journal-title":"Front Neurol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.4103\/0028-3886.241404","article-title":"Pediatric opsoclonus-myoclonus-ataxia syndrome: experience from a tertiary care university hospital","volume":"66","author":"Huddar","year":"2018","journal-title":"Neurol India"},{"key":"R3-20250804","first-page":"176","article-title":"Neuroblastoma and opsoclonus-myoclonus-ataxia syndrome\u2014clinical and pathological characteristics","volume":"46","author":"Stefanowicz","year":"2008","journal-title":"Folia Neuropathol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/practneurol-2011-000017","article-title":"The opsoclonus\u2014myoclonus syndrome","volume":"11","author":"Sahu","year":"2011","journal-title":"Pract Neurol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pediatrneurol.2017.03.011","article-title":"Opsoclonus-myoclonus syndrome: a new era of improved prognosis?","volume":"72","author":"Galstyan","year":"2017","journal-title":"Pediatr Neurol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-911X(199704)28:4<284::AID-MPO7>3.0.CO;2-E","article-title":"Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group","volume":"28","author":"Russo","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14737175.2016.1176914","article-title":"Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment","volume":"16","author":"Blaes","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jpedsurg.2014.03.017","article-title":"Neuroblastoma: outcome over a 14 year period from a tertiary care referral centre in India","volume":"49","author":"Agarwala","year":"2014","journal-title":"J Pediatr Surg"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.1991.9.9.1599","article-title":"Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St Jude Children\u2019s Research Hospital experience, 1962 to 1988","volume":"9","author":"Bowman","year":"1991","journal-title":"J Clin Oncol"},{"key":"R12-20250804","first-page":"CD010774","article-title":"Rapid COJEC versus standard induction therapies for high-risk neuroblastoma","volume":"5","author":"Peinemann","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mpo.1138","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies\u2014a report from the Children\u2019s Cancer Group Study","volume":"36","author":"Rudnick","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/B978-0-444-52910-7.00042-8","article-title":"Opsoclonus-myoclonus syndrome","volume":"112","author":"Pike","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejpn.2009.03.002","article-title":"A prospective study of the presentation and management of dancing eye syndrome\/opsoclonus-myoclonus syndrome in the United Kingdom","volume":"14","author":"Pang","year":"2010","journal-title":"Eur J Pediatr Neurol"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S2352-4642(17)30129-3","article-title":"Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma","volume":"2","author":"Kushner","year":"2018","journal-title":"Lancet Child Adolec Health"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pediatrneurol.2017.04.027","article-title":"Dexamethasone, intravenous immunoglobulin, and rituximab combination immunotherapy for pediatric Opsoclonus-Myoclonus syndrome","volume":"73","author":"Pranzatelli","year":"2017","journal-title":"Pediatr Neurol"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2352-4642(17)30130-X","article-title":"Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial","volume":"2","author":"de Alarcon","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome","volume":"22","author":"Tate","year":"2005","journal-title":"J Pediatr Oncol Nurs"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/pbc.22226","article-title":"Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up","volume":"53","author":"Catsman-Berrevoets","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R23-20250804","article-title":"Opsoclonus-myoclonus syndrome: clinical characteristics, therapeutic considerations, and prognostic factors in a Spanish paediatric cohort","author":"Cantar\u00edn-Extremera","year":"2020","journal-title":"Neurologia"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4103\/aian.AIAN_101_18","article-title":"Clinical profile, prognostic indicators, and therapeutic outcomes of pediatric opsoclonus-myoclonus-ataxia syndrome: a single-center experience from South India","volume":"22","author":"Muthusamy","year":"2019","journal-title":"Ann Indian Acad Neurol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:09:23Z","timestamp":1754338163000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002131","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"2020-08-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}